Standard BioTools Inc.
LAB
$0.90
-$0.06-6.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.96% | -11.47% | -3.25% | -6.61% | -12.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.96% | -11.47% | -3.25% | -6.61% | -12.10% |
| Cost of Revenue | -7.50% | 1.08% | -11.76% | -19.94% | -9.51% |
| Gross Profit | 0.22% | -21.79% | 45.10% | 55.58% | -14.97% |
| SG&A Expenses | -7.25% | 8.70% | 13.05% | 12.91% | 27.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.31% | 4.00% | 2.80% | -0.48% | 10.87% |
| Operating Income | 4.68% | -21.72% | -9.06% | -5.30% | -54.31% |
| Income Before Tax | 18.10% | -50.91% | 28.04% | -44.18% | -34.92% |
| Income Tax Expenses | -13,310.29% | -1,130.51% | -1,661.54% | -205.31% | 267.90% |
| Earnings from Continuing Operations | 151.16% | -44.55% | 30.54% | -42.47% | -37.40% |
| Earnings from Discontinued Operations | 178.01% | 40.17% | 22.14% | 83.10% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 156.59% | -28.77% | 26.81% | 19.04% | -72.29% |
| EBIT | 4.68% | -21.72% | -9.06% | -5.30% | -54.31% |
| EBITDA | -58.34% | -69.40% | -13.71% | -12.59% | 4.47% |
| EPS Basic | 155.05% | -25.10% | 28.42% | 74.12% | 63.31% |
| Normalized Basic EPS | 37.53% | -58.26% | 5.65% | 6.34% | 62.37% |
| EPS Diluted | 155.05% | -25.10% | 28.42% | 74.12% | 64.03% |
| Normalized Diluted EPS | 37.53% | -58.26% | 5.65% | 6.34% | 62.37% |
| Average Basic Shares Outstanding | 2.80% | 2.99% | 2.19% | 28.60% | 369.77% |
| Average Diluted Shares Outstanding | 2.80% | 2.99% | 2.19% | 28.60% | 369.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |